AZD8965 compared with placebo in adults with idiopathic pulmonary fibrosis
Tests 3 doses of AZD8965 against placebo in adults with idiopathic pulmonary fibrosis.
Plain-language title generated from the registry record
Registry title: A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Key facts
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, and Valencia, SpainSee the 5 sites
- Phase
- Phase 2
Where in Spain
- BarcelonaBarcelona, SpainNot yet recruiting
- L'Hospitalet de LlobregatL'Hospitalet de Llobregat, SpainNot yet recruiting
- MadridMadrid, SpainNot yet recruiting
- MálagaMálaga, SpainTaking people
- ValenciaValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07652658
- Record updated
- 29 October 2026
- Original description
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.Read full original descriptionShow less
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)
This Phase IIb study aims to evaluate the efficacy, safety, and tolerability of 3 doses of AZD8965 treatment compared to placebo in participants with IPF, including those on antifibrotic therapy (nintedanib, pirfenidone, nerandomilast), either alone or in combination, or in those not on antifibrotic therapy.
Inclusion: Age ≥ 40 years; IPF diagnosis; Participants with IPF receiving locally approved antifibrotic therapies at a stable dose, or participants with IPF not receiving local standard of care; FVC ≥ 45% predicted of normal; DLCO corrected for hemoglobin ≥ 25% predicted of normal.
Exclusion: Lower respiratory tract infection requiring treatment; Acute coronary syndrome/acute myocardial infarction, unstable angina ± coronary intervention with Percutaneous Coronary Intervention, or Coronary Artery Bypass Grafting; Heart failure; History of organ transplantation or is likely to receive lung transplantation; ILD other than IPF; The extent of emphysema is greater than the extent of fibrotic changes on chest HRCT scan; Acute exacerbation of IPF.